Clinical Research Directory
Browse clinical research sites, groups, and studies.
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Summary
The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.
Official title: Phase I Clinical Study on the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2024-07-31
Completion Date
2025-12-31
Last Updated
2024-07-16
Healthy Volunteers
No
Interventions
UTAA09 injection
The subjects, who sign the informed consent forms and been screeneinclusion/exclusion criteria, will be assigned into 3 x 108\~1 x 1010 CD19-CAR - γδT cells.
Locations (1)
PersonGen.Anke Cellular Therapeutice Co., Ltd.
Hefei, Anhui, China